

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(31) International Patent Classification ⁶ : A61K 39/00, 39/38, 39/40, 39/395, 39/44, 39/42, C07K 1/00, 14/00, 17/00, C12P 21/06, C12Q 1/02	A1	(11) International Publication Number: WO 95/33481 (43) International Publication Date: 14 December 1995 (14.12.95)
(21) International Application Number: PCT/US95/06857 (22) International Filing Date: 31 May 1995 (31.05.95) (30) Priority Data: 08/257,781 8 June 1994 (08.06.94) US (71) Applicants: PRESIDENT AND FELLOWS OF HARVARD COLLEGE [US/US]; 17 Quincy Street, Cambridge, MA 02139 (US). THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US). (72) Inventors: COLLIER, R., John; 43 Garden Road, Wellesley Hills, MA 02181 (US). SHEN, Wei, Hai; P.O. Box 15020, Boston, MA 02215 (US). EISENBERG, David; 342 Comstock Avenue, Los Angeles, CA 90024 (US). CHOE, Seunghyon; 718 Santa Rufina Drive, Solana Beach, CA 92075 (US). (74) Agent: FREEMAN, John, W.; Fish & Richardson P.C., 225 Franklin Street, Boston, MA 02110-2804 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: DIPHTHERIA TOXIN VACCINES BEARING A MUTATED R DOMAIN (57) Abstract Diphtheria toxin polypeptides comprising a mutant R binding domain exhibit reduced target cell binding and may be used as vaccines to immunize a mammal against infection by <i>Corynebacterium diphtheria</i> .		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

DIPHTHERIA TOXIN VACCINES BEARING A MUTATED R DOMAINBackground of the Invention

This invention relates to vaccines which protect
5 against diphtheria toxin.

Wild-type diphtheria toxin (DT) is a protein
exotoxin produced by the bacterium *Corynebacteria*
diphtheria. The molecule is produced as a single
polypeptide that is proteolytically cleaved at amino acid
10 residue 190, 192, or 193 into two subunits linked by a
disulfide bond: fragment A (N-terminal ~21K) and fragment
B (C-terminal ~37K) (Moskaug, et al., *Biol Chem*
264:15709-15713, 1989; Collier et al., *Biol Chem*,
246:1496-1503, 1971). The receptor binding domain of
15 wild-type DT is contained within the B fragment (Rolfe et
al., *J. Biol. Chem.*, *265*:7331-7337, 1990). Fragment A is
the catalytically active portion of wild-type DT. It is
an NAD-dependent ADP-ribosyltransferase which inactivates
protein synthesis factor elongation factor 2 (EF-2),
20 thereby shutting down protein synthesis in the
intoxicated cell. Fragment B of wild-type DT possesses
the receptor-binding domain known as the R domain (amino
acids 379-535, see Choe et al., *Nature*, *357*:216-222,
1992; Fu et al., In *Vaccines 93*, Ginsberg et al., Eds.,
25 *CSHSQB*, pp. 379-383, 1993). The receptor-binding domain
comprises 10 β strands which form two β sheets. A subset
of the β strands resembles an immunoglobulin-like moiety,
which is conceivably involved in receptor recognition
(Choe et al., *Nature* *357*:216-222, 1992). Once DT is
30 bound to the cell via the receptor binding domain, the
receptor/DT complex is internalized. A second functional
region on fragment B acts to translocate DT across the
cell membrane, releasing catalytically active fragment A
into the cytosol of the cell. A single molecule of

- 2 -

fragment A is sufficient to inactivate cellular protein synthesis.

Immunity to a bacterial toxin such as wild-type DT may be acquired naturally during the course of infection, or artificially by injection of a detoxified form of the toxin (also called a chemical toxoid) (Germanier, ed., Bacterial Vaccines, Academic Press, Orlando, Fl., 1984). Chemical toxoids have traditionally been prepared by chemical modification of native toxins (e.g., with formalin or formaldehyde (Lingood et al., *Brit. J. Exp. Path.* 44:177, 1963), rendering them non-toxic while retaining antigenicity that protects the vaccinated animal. An example of a chemical toxoid is that described by Michel and Dirkx (*Biochem. Biophys. Acta* 491:286-295, 1977). However, a chemical toxoid may lose the added chemical group or groups, and revert to its active, toxic form, so that its use as a vaccine poses a risk to the vaccinee.

Another avenue for producing a toxoid is by the use of genetic techniques. A *Corynebacterium diphtheriae* mutant, CRM-197 (Uchida et al., *J. Biol. Chem.* 248:3838-3844, 1973; Uchida, et al., *Nature* 233:8-11, 1971) (CRM standing for "cross-reacting material") was shown to contain an enzymatically inactive DT protein which produces an anti-DT immune response. Collier et al. (U.S. Patent No. 4,709,017; herein incorporated by reference) discloses a genetically engineered DT mutant that bears an amino acid deletion at Glu-148. Substitution of Asp, Gln or Ser at this site diminishes enzymatic and cytotoxic activities by 2-3 orders of magnitude, showing that the spatial location and chemical nature of the Glu-148 side chain greatly affects these activities (Carroll et al., *J. Biol. Chem.* 262:8707, 1987; Tweten et al., *J. Biol. Chem.* 260:10392, 1985; Douglas et al., *J. Bacteriol.* 169:4967, 1987).

- 3 -

Similarly, Greenfield et al. (U.S. Patent No. 4,950,740; herein incorporated by reference) discloses genetically engineered mutant forms of DT in which the Glu 148 residue is deleted or replaced with Asn. The DNA sequence and corresponding amino acid sequence of naturally occurring diphtheria toxin DNA is set forth in Fig. 1 (SEQ ID NO:1).

Summary of the Invention

The invention features polypeptides comprising a mutant diphtheria toxin (toxoid) R domain that can be used as a vaccine against the toxic effects of wild-type (i.e., naturally occurring) DT. The mutant R domain consists of an amino acid segment between amino acids 379-535, inclusive, of SEQ ID NO: 1, which is mutated in at least one amino acid position so as to reduce but not eliminate target cell receptor binding. It is preferable to retain other functional domains in addition to the R domain in such vaccines in order to maximize protein stability and optimize epitope diversity. On the other hand, a vaccine or live vaccine strain comprising a single domain such as the R domain is less likely to revert to toxicity. The invention also features live, genetically engineered microorganisms (cells and viruses) expressing a polypeptide comprising a mutant DT R domain. A toxoid of the invention comprises a mutant R domain that binds target cells with less efficiency than wild-type DT. A toxoid of the invention, and the DNA encoding a toxoid of the invention carry less risk of reversion and are better candidates for use in a live, genetically engineered vaccine cell or virus, each of which is capable of proliferating in the vaccinee. Preferably, the toxoids include a mutant R domain that is immunologically cross-reactive with naturally occurring diphtheria toxin -- i.e., it reacts with antibodies that

- 4 -

are monospecific for naturally occurring diphtheria toxin.

Mutated, or mutant, as used herein, refers to a sequence change (substitution or deletion) which results
5 in a deletion of one or more of amino acids 379-535, or substitution of at least one of those amino acids with one or more other amino acids.

Applicants have shown how to construct DT toxoids comprising a mutant R domain which are safe to administer
10 to a patient in the form of a live vaccine strain. Use of a live vaccine strain has many advantages over immunizing with a chemical toxoid. For example, 1) a live vaccine strain proliferates in the recipient and is capable of expressing a DT toxoid; 2) a live vaccine
15 strain remains in the vaccinee longer than would an injected polypeptide, and is capable of producing a genetically engineered DT toxoid; and 3) a live vaccine may require fewer injections or boosters for effective immunization, can often be orally administered, and can
20 be used to administer multiple antigens at once. Alternatively, toxoids of the invention may be combined with a pharmaceutically suitable vehicle to form a vaccine composition that is inoculated into a mammal, and generates immunological protection against wild-type
25 diphtheria toxin. A toxoid of the invention is produced by culturing a cell that includes a DNA encoding a DT toxoid and regulatory DNA capable of directing expression of the DT toxoid.

In general, the invention features a polypeptide,
30 preferably a substantially pure preparation of a polypeptide, the polypeptide comprising a mutant diphtheria toxin R domain, preferably encoding both a mutant R domain and at least part of the B fragment, or encoding a mutant R domain and at least part of the A
35 fragment, more preferably a mutant R domain and a B

- 5 -

fragment and at least part of an A fragment, most preferably a mutant R domain and the B fragment and all of fragment A, in which the R domain comprises a mutation in at least one or more of Lys 516, Lys 526, Phe 530, or Lys 534 (Fig. 1; SEQ ID NO: 1), preferably the Lys 516, Lys 526, or Lys 534 is replaced by Cys or Phe, and the Phe 530 is substituted by any one of Glu, Lys, or Gln, the B fragment, above, lacking the segment between amino acids 379-535, inclusively of wild-type DT (Fig. 1; SEQ ID NO: 1). A polypeptide of the invention, as used herein, refers to a polypeptide comprising a mutant R domain as exemplified or claimed herein. As used herein, the term "substantially pure" describes a DT protein which has been separated from components which naturally accompany it. Typically, a protein is substantially pure when at least 10% of the total material (by volume, by wet or dry weight, or by mole per cent or mole fraction) is a DT protein. Preferably the protein is at least 50%, more preferably at least 75%, even more preferably at least 90%, most preferably at least 99% of the total material. Purity can be conveniently assayed by well known methods such as SDS-PAGE gel electrophoresis, column chromatography, or HPLC analysis.

In a related aspect, the invention features a cell comprising a nucleic acid encoding a polypeptide of the invention, preferably a homogeneous population of cells, preferably any one of a *B. subtilis*, *Bacillus Calmette-Guerin* (BCG), *Salmonella* sp., *Vibrio cholerae*, *Corynebacterium diphtheria*, *Listeriae*, *Yersinia*, *Streptococci*, or *E. coli* cell. The cell is preferably capable of expressing a polypeptide of the invention.

In another aspect, the invention features a vaccine comprising a physiologically acceptable mixture including a polypeptide of the invention.

- 6 -

In a related aspect, the invention features a live vaccine strain comprising a cell that expresses an above-described polypeptide of the invention.

In another aspect, the invention features a method
5 of preparing a polypeptide of the invention comprising providing a cell growing the cell in a medium to form a population of cells that express the polypeptide and obtaining the polypeptide from a population of cells or the medium.

10 In a related aspect, the invention also features a method for manufacturing a vaccine comprising culturing a cell comprising a polypeptide of the invention under conditions permitting proliferation of the cell, the cell being suitable for introduction into an animal as a live
15 vaccine cell.

The invention also features a method of immunizing a mammal, preferably a human, against wild-type diphtheria toxin, the method comprising introducing an immunizing amount of a vaccine into the mammal. One, but
20 not the only, method of administering a DNA encoding a diphtheria toxoid of the invention is by biolistic transfer, a method of delivery involving coating a microprojectile with DNA encoding an immunogen of interest, and injecting the coated microprojectile
25 directly into cells of the recipient (Tang, et al., *Nature* 356:152-154, 1992; hereby incorporated by reference). The diphtheria toxoid of the invention is then expressed from the DNA to stimulate an immune response in the recipient.

30 In another aspect, the invention features a fusion polypeptide comprising a polypeptide linked by a peptide bond to a second polypeptide. A second polypeptide, as used herein, confers stability to and/or aids or enhances the immunogenicity of a mutant R domain or a polypeptide
35 of the invention.

- 7 -

A fusion polypeptide consists of a polypeptide of the invention linked by a peptide bond to a second polypeptide. Preferably, the fusion polypeptide is included in a vaccine, which can be used to immunize a human patient against wild-type diphtheria toxin. Additionally, a polypeptide of the invention can act as a carrier substance for a second polypeptide, forming a fusion polypeptide and preferably enhancing the immunogenicity of the second polypeptide. The DNA encoding the fusion polypeptide can be used directly as a vaccine, or can be incorporated into a cell, the cell (e.g. a live vaccine cell), is capable of expressing the fusion polypeptide, and, preferably, is used as a vaccine against wild-type diphtheria toxin. "Fusion polypeptide," as used herein, refers to a protein molecule produced by expression of a DNA in which the DNA encodes a polypeptide of the invention, the polypeptide linked by means of genetic engineering to a second DNA encoding a second polypeptide sequence. A "fusion polypeptide of the invention," as used herein, refers to a fusion polypeptide comprising a mutant R domain.

In another aspect, the invention features a DNA molecule comprising a sequence encoding a mutant diphtheria toxin R domain, preferably encoding both a mutant R domain and at least part of the B fragment, or encoding a mutant R domain fragment and at least part of the A fragment, more preferably a mutant R domain and a B fragment and at least part of an A fragment, most preferably a mutant R domain and the B fragment and all of fragment A, where the DNA sequence complimentary to the codon corresponding to at least one of Lys 516, Lys 526, Phe 530, or Lys 534 of naturally-occurring diphtheria toxin (Fig. 1; SEQ ID NO: 1) is mutated, preferably the Lys 516, Lys 526, or Lys 534 is substituted by either Cys or Phe, and the Phe 530 is

- 8 -

substituted by a any one of Glu, Lys, or Gln, the B fragment, above, lacking amino acids 379-535, inclusively.

In another aspect, the invention features a DNA molecule comprising a sequence encoding a mutant diphtheria toxin R domain and at least part of the B fragment, the B fragment comprising a mutation at any one of Glu 349, Asp 352, or Ile 364 of wild-type diphtheria toxin (Fig. 1, SEQ ID NO: 1) and lacking amino acids 379-535, inclusively.

In another aspect, the invention features a DNA molecule comprising a sequence encoding a mutant diphtheria toxin R domain, the B fragment, and at least part of the A fragment, the A fragment comprising a mutation at any one of His 21, Glu 22, Lys 39, Gly 52, Gly 79, Gly 128, Ala 158, Gly 162, Glu 142, Val 147, Glu 148 of wild-type diphtheria toxin (Fig. 1, SEQ ID NO: 1), the B fragment, above, lacking amino acids 379-535, inclusively.

In another aspect, the invention features a DNA sequence encoding the polypeptide encoded by the DNA sequence shown in Fig. 2.

In another aspect, the invention features a polyclonal antibody produced by injecting a mammal with the diphtheria toxin R domain.

In another aspect, the invention features a monoclonal antibody capable of binding the diphtheria toxin R domain.

In a related aspect, the invention features a polypeptide including a mutant R domain, wherein the R domain includes at least one mutation between amino acids 379-535 of SEQ ID NO: 1, inclusive. The polypeptide binds sensitive cells with less affinity than wild-type diphtheria toxin and is capable of forming an immune

- 9 -

complex with an antibody which specifically recognizes the R domain of wild-type diphtheria toxin. A sensitive cell, as used herein, is any cell which is killed by wild-type diphtheria toxin as determined by cytotoxicity assays described herein.

In a related aspect, the invention features a DNA molecule including a sequence encoding a mutant diphtheria toxin R domain, wherein the DNA sequence complimentary to a codon corresponding to at least one amino acid between 379-535 of SEQ ID NO: 1, inclusive, is mutated.

A "live vaccine cell," or "live vaccine strain," as used herein, is either a naturally avirulent live microorganism, or a live microorganism with either low or attenuated virulence, that expresses an immunogen.

The invention also features polypeptides that are covalently attached to a moiety, e.g., a polysaccharide or a second polypeptide. The moiety may serve as a carrier substance for a polypeptide of the invention; or, alternatively, a polypeptide of the invention can serve as a carrier substance for the moiety, preferably enhancing the immunogenicity of the moiety. Preferred polysaccharides include dextran, PrP (the capsular polysaccharide of *H. influenzae* b) and pneumococcal polysaccharides (types 14, 6B or 23F). A "carrier substance" is a substance that confers stability to, and/or aids or enhances the transport or immunogenicity of, an associated molecule.

In a related aspect, the invention features a polypeptide of the invention comprising a carrier substance which enhances the immunogenicity of a moiety or the polypeptide. Examples of preferred carrier substances have been listed above.

A polypeptide or fusion protein of the invention can be made by any suitable method, preferably by

- 10 -

culturing any of the various cells containing a DNA encoding a diphtheria toxoid of the invention under conditions permitting the expression of the DNA.

Expression of a diphtheria toxoid of the invention
5 is under the control of a heterologous promoter, and/or the expressed amino acids are linked to a signal sequence. Vectors comprising DNA encoding toxoids of the invention can be made by molecular techniques well known in the art (See Sambrook et al., *Molecular Cloning*, 2nd
10 ed., (1989)). By "heterologous promoter" is meant a promoter region that is not identical to the promoter region found in a naturally occurring diphtheria toxin gene. The promoter region is a segment of DNA 5' to the transcription start site of a gene, to which RNA
15 polymerase binds before initiating transcription of the gene.

An "essentially pure" preparation of the nucleic acid of the invention is a preparation containing the nucleic acid of the invention, and which is substantially
20 free of other nucleic acid molecules with which a nucleic acid encoding wild-type diphtheria toxin is naturally associated in *Corynebacterium*.

Wild-type or naturally occurring DT, as used herein, refers to the diphtheria toxin protein found in
25 nature as shown in SEQ ID NO: 1. Pseudo-wild-type DT, as used herein, refers to the diphtheria toxin protein comprising a Glu → Ser mutation at amino acid 148. Those skilled in the art will know that, in the laboratory, handling pseudo-wild-type DT is safer than handling wild-
30 type DT. A mutant DT protein, as used herein, is DT protein comprising a mutant R domain as exemplified herein. Polypeptides of the invention that are "immunologically cross-reactive," as that term is used herein, possess at least one antigenic determinant in
35 common with naturally occurring diphtheria toxin, so that

- 11 -

they are each bound by at least one antibody with specificity for naturally occurring diphtheria toxin.

Other features and advantages of the invention will be apparent from the following detailed description 5 and from the claims.

Detailed Description

We first briefly describe the drawings.

Drawings

Fig. 1 is a drawing of the DNA vector PWHS-105 10 comprising the DT gene. HindIII and NdeI restriction enzyme sites are indicated. 6 X His refers to six consecutive histidine residues used to purify the DT protein.

Table I is a list of mutations in the diphtheria 15 toxin R domain made by site directed mutagenesis.

Table II is the result of testing the cytotoxicity of wild-type DT, pseudo-wild-type DT, and various mutant DT proteins.

- 12 -

Methods1. Cloning and Expression of the DT Gene

The DT gene (O'Keefe et al., PNAS (USA) 86: 343-346, (1989)) was PCR-amplified, then cut with NdeI and Hind III. The gene fragment has inserted into a PET-15b expression vector (Novagen) in order to make PWHS105. By using this vector, and the manufacturer's instructions, the expressed DT protein carries six consecutive histidine residues at the N-terminal end. The modified vector comprising the DT gene was termed PWHS105 (Fig. 1). Multiple histidine residues bind the DT protein to a Ni²⁺-column prepared according to the manufacturer's instructions (Novagen). After unbound proteins were washed away, the DT protein was collected by elution with imidazole. DT protein purity is above 99% with this method, and the yield is - 1-2 mg per 50 ml bacterial culture. Bacterial transformation was accomplished according to standard procedures (Sambrook et al., *Molecular Cloning*, (1989) pp. 1.74-1.105).

20 I. Alternative DNA Vectors

DNA encoding DT or a polypeptide of the invention may also be carried on any other vector operably linked to control signals capable of effecting expression in a prokaryotic host. If desired, the coding sequence can contain, at its 5' end, a sequence encoding any of the known signal sequences capable of effecting secretion of the expressed protein into the periplasmic space of the host cell, thereby facilitating recovery of the protein. Prokaryotes most frequently used are represented by various strains of *E. coli*; however, other microbial strains can also be used, e.g., *C. diphtheriae*. Additional plasmid vectors may be used which contain replication origins, selectable markers, and control sequences derived from a species compatible with the microbial host. For example, *E. coli* can be transformed

- 13 -

using derivatives of PBR322, a plasmid constructed by Bolivar, et al. (1977, *Gene* 2:95) using fragments derived from three naturally-occurring plasmids, two isolated from species of *Salmonella*, and one isolated from *E. coli*. PBR322 contains genes for ampicillin and tetracycline resistance, and thus provides multiple selectable markers which can be either retained or destroyed in constructing the desired expression vector. Commonly used prokaryotic expression control sequences (also referred to as "regulatory elements") are defined herein to include promoters for transcription initiation, optionally with an operator, along with ribosome binding site sequences. Promoters commonly used to direct protein expression include the beta-lactamase (penicillinase), the lactose (*lac*) (Chang et al., 198 *Nature* 1056, 1977) and the tryptophan (*trp*) promoter systems (Goeddel et al., 8 *Nucl. Acids Res.* 4057, 1980) as well as the lambda-derived P_L promoter and N-gene ribosome binding site (Shimatake et al., 292 *Nature* 128, 1981). Examples of microbial strains, vectors, and associated regulatory sequences are listed herein to illustrate, but not to limit, the invention.

By way of example, vectors other than PET-15b (Novagen) can be used to express the polypeptides of the invention, or a fusion protein including the polypeptides of the invention. These vectors may consist of (i) an origin of replication functional in *E. coli* derived from the plasmid PBR322; (ii) a selectable tetracycline resistance gene also derived from PBR322; (iii) a transcription termination region, e.g., the termination of the *E. coli* *trp* operon (placed at the end of the tetracycline resistance gene to prevent transcriptional read-through into the *trp* promoter region); (iv) a transcription promoter, e.g., the *trp* operon promoter, or the diphtheria toxin promoter; (v) the R region protein

- 14 -

coding sequence; and (vi) a transcription terminator, e.g., the T1T2 sequence from the ribosomal RNA (rrnB) locus of *E. coli*. The sequences of carrier molecules, the methods used in the synthesis of the DNA sequences, 5 the construction of fusion genes, and the appropriate vectors and expression systems are all well known to those skilled in the art. Similar expression systems can be designed for fusion or non-fusion polypeptides, i.e., for expression of the R region polypeptide alone. These 10 procedures are further examples of, but are not limiting on, the methods of the invention.

II. Alternative Protein Purification and Synthesis

One schooled in the art can purify polypeptides of the invention using other conventional methods of protein 15 isolation, e.g., methods including but not limited to precipitation, chromatography, immunoadsorption, or affinity techniques. The polypeptides can be purified from starting material using protease-treated diphtheria toxin, or using the cells, or medium of the cells, of a 20 vaccine strain genetically engineered to express a polypeptide of the invention. Purification can also be achieved by making another fusion protein of a polypeptide with another recombinant protein, e.g., with a fragment of the maltose binding protein in a manner 25 similar to that described above. These fusion constructs can be made, for example, with the vector PMAL (New England Biolabs) or the PGEX-3X or -2T vectors (Pharmacia), described above. Fusion proteins are purified on affinity columns specific for the maltose 30 binding protein or the glutathione-S-transferase protein, respectively.

Polypeptides of the invention can, in some cases, also be synthesized by non-biological means, for example organic chemical synthesis, or cleaved from a larger 35 protein containing the amino acid sequences of the

- 15 -

invention. For example, organic chemical synthesis can be performed by conventional methods of automated peptide synthesis, or by classical organic chemical techniques. Diphtheria toxin protein or fragment B can be purified, for example, by the method of Carroll et al. (Meth Enzymol 165:68-76, 1988).

2. Characterization of Diphtheria Toxin Cytotoxicity

The cytotoxicity of pseudo-wild-type DT and wild-type DT was evaluated in a cytotoxicity assay (Meth. in Enz. 165:220-221, 1988, herein incorporated by reference). The data show pseudo-wild-type DT has an ID50 value of 3.8×10^{-11} M, while the ID50 value of wild-type DT is 10^{-13} M. The difference in cytotoxicity between these two proteins is due to the mutation of the A fragment active site at amino acid 148 of DT. Polypeptides of the invention may be tested for cytotoxicity in this assay. Additional embodiments of the assay include adding both a polypeptide of the invention and wild-type DT to cells in order to check for the ability of a polypeptide of the invention to block the toxic activity of wild-type DT. In another embodiment of the cytotoxicity assay, it is possible to screen antibodies which bind wild-type DT or a polypeptide of the invention by combining each with an antibody under conditions which allow binding of the antibody to the polypeptide or wild-type DT and checking for cell toxicity in the cytotoxicity assay. Antibodies capable of binding wild-type DT or a polypeptide of the invention will prevent cell toxicity.

3. Site-Directed Mutagenesis of DT

To identify amino acids in the diphtheria toxin R domain involved in receptor binding and to make mutant DT proteins, we used well known DNA primer based site-directed mutagenesis (site directed mutagenesis (M13) kit

- 16 -

from Amersham). Specific DNA primers used for site directed mutagenesis are disclosed (SEQ ID NOs: 3-28). The Amersham kit was used according to the manufacturer's instructions in order to mutate specific residues within the R domain. We produced a total of twenty-four mutant DT proteins (see Table 1). Mutant DT proteins were purified by a Ni^{2+} -column (Novagen) according to the manufacturer's instructions.

10 4. Amino Acid Positions 516 and 530 Are Receptor Binding Sites

Cells which are sensitive to diphtheria toxin possess cell receptors which bind and internalize the toxin. Generally, such cells are killed when exposed to wild-type diphtheria toxin. The ability of purified mutant DT proteins to bind cells via a diphtheria toxin receptor was evaluated by cytotoxicity assay (above). The results of the cytotoxicity assay using pseudo-wild-type DT (so called "WT" in Table 2) and selected DT mutant proteins are shown in Table 2. In Table 2, a DT mutant protein is given two letters and a number as a convenient abbreviation. The first letter refers to the normal amino acid, the number is the amino acid residue in SEQ ID No: 1, and the last letter, the substituted amino acid of the mutant protein. The mutant DT protein K516A has 1/20 the toxicity of DT. Given that pseudo-wild-type DT has roughly 1/400 of the toxicity of wild-type DT, K516A has 1/8000 the toxicity of wild-type DT. The mutant protein F530A is less toxic than DT by a factor of 9 and has 1/3500 the toxicity of the wild-type DT. These data confirm that Lys 516 and Phe 530 are important for the binding of wild-type diphtheria toxin to diphtheria toxin receptors on the cells. Moreover, the conservative change from lysine to glutamic acid at amino acid 516 demonstrates that the positive charge of 516K contributes to the binding activity of wild-type diphtheria toxin.

- 17 -

TABLE 1

DT Mutant List

<u>Amino Acid</u>	<u>Amino Acid Mutation</u>	<u>Codon Mutation</u>	<u>Amino Acid</u>	<u>Amino Acid Mutation</u>	<u>Codon Mutation</u>
510 Gly	→ Ser,	GGC → AGT			
512 Leu	→ Glu,	CTT → GAA			
514 Tyr	→ Ala,	TAC → GCC	514 Tyr	→ Ala,	TAC → GCC
516 Lys	→ Glu,	AAA → GAA	516 Lys	→ Ala,	AAA → GCA
518 Val	→ Glu,	GTA → GAA	518 Val	→ Ala,	GTA → GCA
520 His	→ Asp,	CAC → GAC	520 His	→ Ala,	CAC → GCC
521 Thr	→ Arg,	ACC → CGC	521 Thr	→ Ala,	ACC → GCC
522 Lys	→ Glu,	AAG → GAG	522 Lys	→ Ala,	AAG → GCG
523 Val	→ Glu,	GTT → GAA	523 Val	→ Ala,	GTT → GCT
524 Asn	→ Ala,	AAT → GCT	524 Asn	→ Ala,	AAT → GCT
525 Ser	→ Phe,	TCT → TTT	525 Ser	→ Ala,	TCT → GCT
526 Lys	→ Glu,	AAG → GAG	526 Lys	→ Ala,	AAG → GCG
528 Ser	→ Tyr,	TCG → TAT	528 Ser	→ Ala,	TCG → GCG
530 Phe	→ Ser,	TTT → TCT	530 Phe	→ Ala,	TTT → GCT

TABLE 2

DT,M	10^{-12}	10^{-11}	2×10^{-11}	4×10^{-11}	8×10^{-11}	10^{-10}	2×10^{-10}	4×10^{-10}	8×10^{-10}	10^{-9}	10^{-8}	ID50 10^{-11}	ID50 relv.
WT	.953	.805	.728	.47	.247	.169	.085	.04	.028	.023	.018	3.77	1
Y514A	1.01	1.06	1.01	.983	.832	.706	.452	.288	.193	.190	.142	12.2	3
K516A	.846	.869	.805	.875	.821	.900	.797	.674	.508	.438	.057	82.3	20
V518A	.905	.925	.821	.739	.522	.448	.253	.118	.067	.058	.037	8.6	2
H520A	.979	.916	.677	.477	.256	.215	.097	.047	.036	.037	.026	3.8	1
T521A	.947	.840	.744	.518	.254	.197	.093	.050	.036	.030	.023	4.3	1
K522A	.952	.902	.781	.575	.337	.257	.125	.047	.028	.022	.014	5.3	1
V523A	1.02	1.01	.975	.929	.814	.724	.51	.312	.154	.128	.058	21.0	5
N524A	.904	.89	.89	.771	.607	.552	.34	.155	.074	.067	.020	12.5	3
S525F	1.02	.978	.937	.957	.80	.744	.566	.325	.177	.134	.043	25.5	6
S525A	.897	.767	.654	.524	.263	.205	.089	.035	.022	.021	.016	4.4	1
K526A	.95	.905	.883	.856	.72	.72	.46	.455	.14	.092	.029	23.0	6
S528A	.942	.935	.865	.704	.457	.373	.193	.069	.043	.039	.030	7.3	2
F530A	.873	.82	.835	.858	.851	.783	.649	.37	.211	.178	.065	30.7	9

- 19 -

5. Binding Competition between ^{125}I -Labelled
Wild-Type DT and Mutant DT Proteins

Wild-type and mutant DT proteins were labelled
with ^{125}I by standard methods (see Bolton-Hunter, *Biochem*
5 *J.*, 133:529, 1973) to further demonstrate that amino
acids at positions 516 and 530 are involved in receptor
binding. At 4°C the affinity of both DT mutant proteins
K516A and K516E are 1/500 of DT, and the affinity of both
DT mutant proteins F530A and F530S are 1/100 that of DT.

10 6. Preparation of Antisera Against
the R Domain of Wild-Type DT

The purified receptor binding domain of wild-type
DT (See Choe et al., *supra*) was used as antigen to
produce polyclonal antibody. The immunogenicity of the
15 receptor binding domain protein was tested in two white
New Zealand female rabbits. 1ml of 350 μg of DTR in Tris
buffer, Ph 8.0, was mixed with 1 ml of complete Freund's
adjuvant for the first dose and incomplete Freund's
adjuvant for subsequent doses. Immunizations were given
20 at 0, 20, 40, and 60 days. Serum samples were taken at
30, 50, and 70 days. Antisera were able to recognize not
only the receptor binding domain, but also wild-type DT
in standard Western blotting experiments (see Harlow and
Lane in *Antibodies, a Laboratory Manual*, (1988)).
25 Specific reactivity was observed after the first boost at
12,800-fold dilution and increased after the second and
third boost in ELISA assays (See Harlow and Lane, *supra*).

A 10-fold dilution of the antisera was tested for
ability to neutralize the toxic effect of wild-type DT on
30 Vero cells. Briefly, wild-type DT (10^{-12}M) was incubated
with various concentrations of antisera for 1 hr at 37°C
with Vero cells. Cytotoxicity was evaluated as
previously described (Carrol and Collier, *supra*). After

- 20 -

the third boost, the antisera was able to neutralize up to 72% of the toxicity of wild-type DT.

The ability to efficiently raise antibodies against the receptor binding domain, as demonstrated herein, suggests that the use of a polypeptide comprising a mutant R-domain or the mutant R domain alone could provide an effective vaccine with less or no toxicity. Having demonstrated that polyclonal antisera against the receptor binding domain of wild-type DT is readily obtained, those skilled in the art would know that a monoclonal antibody could also be obtained by following standard immunological methods (see Harlow and Lane, *supra*). The immunogenicity of the receptor binding fragment indicates that a polypeptide comprising a mutant R domain is also immunogenic and prophylactic against exposure to wild-type DT. Polyclonal or monoclonal antibodies against the receptor binding domain of wild-type DT can be used to test whether a polypeptide of the invention is antigenic (see below).

20 I. Western Blotting

0.5 μ g of wild-type DT was loaded onto a divided 12% polyacrylamide minigel. After electrophoresis, the protein was transferred to a nitrocellulose membrane. The membrane bearing transferred protein was cut into pieces and incubated with various dilutions of antisera, separately. The sectioned membranes were then incubated with first antibody, Diphtheria Antitoxin USP (Connaught Laboratories, Inc.), followed by second antibody, anti-horse IgG alkaline phosphatase conjugate (Sigma) and developed with Tris buffer, Ph 9.6, containing 0.01% of nitroblue tetrazolium and 0.01% of 5-bromo-4-chloro-3-indolyphosphate (Sigma).

7. Evaluation of Antigenicity

It is possible to conveniently test whether a polypeptide of the invention is antigenic and likely to

- 21 -

serve as an effective vaccine by exhibiting desirable antigenic properties. Standard diphtheria antitoxin and polyclonal antisera against the purified receptor binding domain of wild type DT can be used to establish the antigenicity of polypeptides of the invention.

(i) Total Antigenic Activity (Lf): The antigenic activity of each purified polypeptide of the invention in terms of flocculating units (Lf) can be measured by the standard flocculation reaction against standard diphtheria antitoxin from the Center for Biologics Evaluation and Research, FDA, Bethesda, MD. The test will be performed by the method of Ramon Relyveld, E. M. (1969) Prog. in Immun. Stand. 3, 258-263. Activity will be expressed in Lf/mg protein.

(ii) Evaluation of Antigenicity with Polyclonal Antisera: Polyclonal antisera against the purified receptor binding domain of wild-type DT can be used to bind polypeptides of the invention. The preservation of antigenic epitopes of wild-type DT in polypeptides of the invention will be evaluated quantitatively in two systems, the classical quantitative precipitin reaction (above) and by competitive ELISA (see Harlow and Lane, *supra*).

(iii) Quantitative Precipitin Reaction: This method has the advantage of allowing antibodies (e.g., standard diphtheria antitoxin or polyclonal sera against purified DT receptor binding domain) to bind polypeptides in the fluid phase, avoiding the potentially distorting effects that can be observed when proteins are bound to nitrocellulose. In addition, it provides precise quantitative information of the amount of antibody precipitable by each polypeptide of the invention. The maximal precipitable antibody will be quantitated using the method of Pappenheimer et al. (*Immunochemistry* 9, 891-906 (1992)). Purified wild-type diphtheria toxin,

- 22 -

formalinized diphtheria toxin (i.e. chemical toxoid) and a polypeptide of the invention will be used as controls. These controls can be used to precipitate diphtheria toxin directed antibodies. The total antibody protein precipitable by each polypeptide will be expressed as a proportion of the antibody precipitable by the control toxins or toxoids and will serve as a measure of how well all diphtheria antigenic epitopes have been preserved in the polypeptides of the invention.

10 The supernatants of the quantitative precipitin reactions will be evaluated for their remaining antitoxin activity at their point of equivalence (point where maximal toxin protein and antibody are precipitated). The control toxin proteins are expected to precipitate all neutralizing activity. The completeness of the precipitation of neutralizing activity by polypeptides of the invention will provide a quantitative measure of how well neutralizing epitopes have been preserved in the mutant polypeptides of the invention.

20 (iv) Competitive ELISA: This assay has the advantage of simplicity. In this assay, the binding of standard diphtheria antitoxin to highly purified wild-type DT coated on ELISA plates can be inhibited by pre-incubation of the antibody (at a dilution giving 80-90% of maximal OD) with serial dilutions of wild-type toxin or formalized DT (controls) or with a mutant polypeptide of the invention. Two useful endpoints are 1) the concentration of wild-type toxin or mutant polypeptide required to inhibit binding of 50% of the antibody and 2) the maximum inhibition achieved with the polypeptides of the invention. The former provides a measure of the relative antigenicity of a polypeptide of the invention and wild-type toxin. The latter demonstrates whether all epitopes are preserved on the polypeptide. If antibodies to epitopes are not bound, the ELISA curve plateaus above

- 23 -

the background level reached with control diphtheria toxin.

8. Evaluation of Immunogenicity A polypeptide of the invention can be tested for immunogenicity by immunizing mice and guinea pigs. Mice are more convenient and cheaper to use, and reagents for class and subclass specific antibody assays are readily available. Assays for murine antibodies have been established and standardized (see Harlow and Lane, supra). A disadvantage of mice is that they are not susceptible to diphtheria toxin because they do not have wild-type DT-binding receptors on their cells. If clearance of toxin by these receptors is responsible for the poor immunogenicity of polypeptides with intact receptor binding function, then one would not detect this problem by immunizing mice. In this case immunize guinea pigs, which are highly susceptible to diphtheria toxin, can be used. In addition, guinea pigs are the test animal for measuring the potency of diphtheria vaccine according to the U.S. Code of Federal Regulations.

(i) Screening for Immunogenicity Polypeptides of the invention will be screened for immunogenicity by giving a high dose of antigen adsorbed to aluminum phosphate to mice and guinea pigs, and measuring antibody responses at 4 weeks in both animals and also at 6 weeks in guinea pigs.

(ii) Immunization of Mice The immunizing dose for mice will be 25 μ g mutant polypeptide/mouse subcutaneously given to groups of 5 mice. Controls will receive 1 μ g formalinized diphtheria toxoid adsorbed on AlPO_4 licensed for use in pediatric vaccine. This dose produces high titers on IgG and neutralizing antibodies in mice. Four weeks after immunization, IgG anti-DT antibody will be measured by ELISA using wild-type diphtheria toxin and a polypeptide of the invention used

- 24 -

for immunization. A pool of sera from each group of 5 mice will also be evaluated for antitoxin activity by Vero cell cytotoxicity assay (supra).

(iii) Immunization of Guinea Pigs The immunizing dose for guinea pigs will be 100 μ g/animal subcutaneously given to groups of 5 animals. Controls will receive 10 Lf (25 μ g) formalinized diphtheria toxoid which represents 1.5 single childhood doses of diphtheria toxoid as specified in the official U.S. potency test. Polyclonal IgG antibody concentrations in individual animals and antitoxin activity by Vero cell cytotoxicity assay in serum pools will be measured at 4 and 6 weeks. If no antibody responses are observed to a construct, one can, as appropriate, treat the construct with formalin in the presence of 0.01 M lysine as described by Relyveld (supra) and reevaluate immunogenicity.

Constructs showing immunogenicity by one or more of these assays will be evaluated further for dose response and binding specificity of the antibodies induced, as described below.

(iv) Quantitative Evaluation of Immunogenicity of Diphtheria Toxin Constructs Groups of 5 - 10 mice will be immunized with doses of polypeptides of the invention ranging over a 100-fold dose range 0.04, 0.2, 1.0, 5.0 and 25 μ g. Typically, the antigen will be adsorbed to a constant amount of aluminum phosphate, but in some instances one can also evaluate the response to soluble antigen. A booster will be given at 4 weeks, when a peak response to the primary dose has occurred and serum can be evaluated according to the following scheme.

<u>WEEK:</u>	0	4	6
Immunization	X	X	
Serum for IgG ELI		X	X
Pooled serum for an		X	X

- 25 -

Control mice can receive similar doses of formalinized DT toxoid. The immunogenicity of polypeptides of the invention relative to wild-type diphtheria toxoid will be compared for both total IgG
5 antibody and neutralizing activity.

(v) Diphtheria Toxoid Potency Test in Guinea Pigs

For polypeptides of the invention that are sufficiently immunogenic to be considered potential candidates for investigation in humans, we will evaluate
10 immunogenicity in guinea pigs according to the official U.S. CFR potency test. The antitoxin induced will be evaluated in vivo to determine whether the minimum required titer of 2 Antitoxin units (AU) has been reached. Endpoint antitoxin titration will be done by
15 the Vero cell cytotoxicity assay (*supra*).

(vi) Evaluation of Diphtheria Mutant Polypeptides with Terminal Hexa-Histidines PET-15b DNA vectors (Novagen) that encode polypeptides of the invention which are effective in inducing high levels of neutralizing
20 antibody and containing an N-terminal hexa-histidine moiety will be evaluated to determine whether they induce specific antibody to the hexa-histidine peptide. Antigens with a longer 12 amino acid N-terminal tag including hexa-histidine have shown to induce small
25 amounts of antibody. This issue can be evaluated by using as targets in ELISA non-diphtheria proteins with N-terminal hexa-histidines and hexa-histidine peptides coupled to plastic with or without a spacer peptide.

(vii) Evaluation of Diphtheria Toxin Polypeptides as Carrier Proteins for Conjugates Using the chemical
30 coupling procedures described below, polysaccharides from *H. influenzae* b or one of the common pneumoccal types (type 14, 6B or 23F) will be covalently linked to

- 26 -

polypeptides of the invention comprising one or more cysteines.

9. Preparation and Use of a Polypeptide Vaccine

A polypeptide toxoid of the invention can be
5 expressed in any known protein expression system and then purified by standard means (see above methods).

A purified polypeptide of the invention may be combined with a physiologically acceptable carrier (such as physiological saline); with an adjuvant that increases
10 immunogenicity (such as aluminum salts, bacterial endotoxins or attenuated bacterial strains (e.g., BCG or *Bordetella pertussis*, attenuated viruses, liposomes, microspheres, or Freund's complete or incomplete adjuvant); and/or with additional toxoids or killed or
15 other vaccine strains (to form a multivalent vaccine). Such a vaccine may then be administered to a human subject by any acceptable method, including but not limited to oral, parenteral, transdermal and transmucosal delivery. Administration can be in a sustained release
20 formulation using a biodegradable biocompatible polymer, such as a microsphere, by on-site delivery using micelles, gels or liposomes, or by transgenic modes (e.g., by biolistic administration of the DNA of the invention directly into the patient's cells, as described
25 by Tang et al., *Nature* 356:152-154, 1992, herein incorporated by reference).

10. Preparation and Use of Live Recombinant Vaccines

Appropriate live carrier organisms include
30 attenuated microorganisms such as BCG, *Salmonella sp.*, *E. coli*, *Vibrio cholerae*, *Streptococci*, *Listeriae*, and *Yersinia*. The DNA of the invention can be stably transfected into such a microbial strain by standard methods (Sambrook et al., *Molecular Cloning: A Laboratory*
35 *Manual*. Cold Spring Harbor Lab. Press, New York, 1989.), and introduced into a patient by, for example, oral or

- 27 -

parenteral administration. Once introduced into the patient, the bacterium would multiply and express a mutant form of diphtheria toxin within the patient, causing the patient to maintain a protective level of antibodies to the mutant toxin. In a similar manner, an attenuated animal virus such as adenovirus, herpes virus, vaccinia virus, polio, fowl pox, or even attenuated eukaryotic parasites such as *Leishmania* may be employed as the carrier organism. A DNA of the invention comprising a mutant R domain can be incorporated by genetic engineering techniques into the genome of any appropriate virus, which is then introduced into a human vaccinee by standard methods. A live vaccine of the invention can be administered at, for example, about 10^4 - 10^8 organisms/dose, or a dose that is sufficient to stably induce protective levels of antitoxin. Actual dosages of such a vaccine can be readily determined by one of ordinary skill in the field of vaccine technology.

11. Preparation of Polypeptide Polysaccharide Conjugates

Conjugate proteins comprising a polypeptide may be prepared as follows:

Polysaccharides may be derivatized by adipic acid dihydrazide using CNBr to introduce hydrazide groups into the polysaccharide. The hydrazide groups are iodoacetylated with N-iodoacetyl-B-alanine-N-hydroxysuccinimide. The protein can be thiolated with N-succinimidyl-S-acetylthioacetate. The activated polysaccharide and thiolated protein can be combined to form thioether bonds between them. A detailed protocol may be found in Anderson, et al., *J. of Immunol.* 142:2464-2468 (1989). The conjugates can be evaluated for immunogenicity as described previously.

12. Administration and In Vivo Testing of a Vaccine

Polypeptides of the invention or the receptor binding domain of wild-type DT can be administered to a

- 28 -

mammal, particularly a human, by any appropriate method: e.g., orally, parenterally, transdermally, or transmucosally. Administration can be in a sustained release formulation using a biodegradable biocompatible polymer, by on-site delivery using micelles, gels and liposomes, or by transgenic modes. Therapeutic doses can be, but are not necessarily, in the range of 0.1 - 10.0 mg/kg body weight, or a range that is clinically determined as appropriate by those schooled in the art.

Guinea pigs (or another species which is naturally sensitive to the cell-killing effects of diphtheria toxin) can be immunized with a toxoid of the invention according to the following protocol: between 1 and 50 μ g toxoid, suspended in 50-100 μ l of Freud's complete adjuvant, is subcutaneously injected into a guinea pig on day 1, day 12, and day 24. Blood samples are then assayed for antitoxin antibodies by testing serial dilutions for reactivity to naturally occurring diphtheria toxin. (See above methods.) Those animals which received high enough doses of toxoid to induce antitoxoid formation as determined by Western Blotting or ELISA can be challenged with wild-type diphtheria toxin, in order to see whether the antibodies are protective. Those toxoids of the invention which induce a positive response in the above assay are likely candidates for incorporation into live vaccines.

Appropriate live vaccine microorganisms (cells or viruses) genetically engineered to express a toxoid of the invention can be tested by injecting the candidate vaccine into an animal sensitive to wild-type DT, for example, a guinea pig, and, after a 2-3 month incubation period, challenging the animal with either a) a lethal dose of wild-type DT, or b) multiple, serially administered doses of wild-type DT, so as to calibrate the range of acquired immunity.

- 29 -

A polypeptide of the invention or the receptor binding domain of wild-type DT which protects against wild-type DT can be administered directly to a human patient as the immunogen in a vaccine against diphtheria toxin. Alternatively, a polypeptide of the invention or the receptor binding domain of wild-type DT can be administered in a live vaccine strain. An administered live vaccine strain can proliferate, express the cloned protective protein antigen, and confer protection from both the attenuated organism itself, wild-type DT, or from the cloned antigen, e.g., a polypeptide of the invention or the receptor binding domain of wild-type DT. Examples of live vaccine strains include, but are not limited to, *BCG*, *Salmonella sp.*, and *Vibrio cholerae*. Transformation of one of these strains with DNA encoding a polypeptide of the invention can be accomplished by conventional methods known to those schooled in the art, for example, calcium phosphate precipitation or electroporation.

A vaccine can also be carried by an attenuated virus, such as adenovirus, herpes virus, or vaccinia virus. Alternatively, the vaccine can be administered by biolistic transfer, which incorporates the DNA encoding an expressible form of a polypeptide of the invention or the receptor binding domain of wild-type DT directly into cells of the vaccinee.

- 30 -

Other Embodiments

Polypeptides comprising a mutant R domain may also bear another mutation, preferably within the Diphtheria toxin catalytic region, in order to hinder catalysis and make said polypeptides safer to use. For example, a mutant form of diphtheria toxin fragment A can be generated which lacks Glu 142, Val 147 and Glu 148, or which lacks all of the residues from Glu 142 to Glu 148, inclusive. Such a mutant fragment A can be combined with a mutant R domain of the invention by using molecular techniques well known in the art. Other amino acid residues that have been shown to be essential for the biological activity of diphtheria toxin include residues His 21, Glu 22, Lys 39, Gly 52, Gly 79, Gly 128, Ala 158, and Gly 162 of the fragment A portion of diphtheria toxin, and residues Glu 349, Asp 352, and Ile 364 of the fragment B portion. Mutations in any one or more of these residues, in addition to mutations in both Val 147 and Glu 148, may be combined with the mutant R domain polypeptides of the invention by using molecular techniques well known in the art. Such mutant diphtheria toxin polypeptides comprising a mutant R domain and at least one of the additional amino acid changes in the A or B fragment described above, may be good candidates for a vaccine exhibiting little or no toxicity.

What is claimed is:

- 31 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Collier, R. John
Shen, Wei Hai
Eisenberg, David
Choe, Seunghyon
- (ii) TITLE OF INVENTION: DIPHTHERIA TOXIN VACCINES
BEARING A MUTATED R
DOMAIN
- (iii) NUMBER OF SEQUENCES: 28
- (iv) CORRESPONDENCE ADDRESS:
- (A) ADDRESSEE: Fish & Richardson P.C.
(B) STREET: 225 Franklin Street
(C) CITY: Boston
(D) STATE: Massachusetts
(E) COUNTRY: U.S.A.
(F) ZIP: 02110-2804
- (v) COMPUTER READABLE FORM:
- (A) MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
(B) COMPUTER: IBM PS/2 Model 50Z or 55SX
(C) OPERATING SYSTEM: MS-DOS (Version 5.0)
(D) SOFTWARE: WordPerfect (Version 5.1)
- (vi) CURRENT APPLICATION DATA:
- (A) APPLICATION NUMBER:
(B) FILING DATE:
(C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
- (A) APPLICATION NUMBER: 08/257,781
(B) FILING DATE: 08 June 1994
- (viii) ATTORNEY/AGENT INFORMATION:
- (A) NAME: John W. Freeman
(B) REGISTRATION NUMBER: 29,066
(C) REFERENCE/DOCKET NUMBER: 00246/174001

- 32 -

(ix) TELECOMMUNICATION INFORMATION:

(A) TELEPHONE: (617) 542-5070
 (B) TELEFAX: (617) 542-8906
 (C) TELEX: 200154

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 1:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1942
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

CCGGCGTTGC GTATCCAGTG GCTACACTCA GGTGTGAATG ATTGGGATGA TGTACCTGAT 60
 CTGAGAGCGA TTA AAAACTC ATTGAGGAGT AGGTCCCGAT TGGTTTTTGC TAGTGAAGCT 120
 TAGCTAGCTT TCCCCATGTA ACCAATCTAT CAAAAAAGGG CATTGATTTC AGAGCACCTT 180
 TATAATTAGG ATAGCTTTAC CTAATTATTT TATGAGTCCT GGTAAAGGGGA TACGTTGTGA 240
 GCAGAAAACT GTTTGCGTCA ATCTTAATAG GGGCGCTACT GGGGATAGGG GCCCCACCTT 300
 CAGCCCATGC A 311
 GGC GCT GAT GAT GTT GTT GAT TCT TCT AAA TCT TTT GTG ATG GAA AAC 359
 Gly Ala Asp Asp Val Val Asp Ser Ser Lys Ser Phe Val Met Glu Asn
 1 5 10 15
 TTT TCT TCG TAC CAC GGG ACT AAA CCT GGT TAT GTA GAT TCC ATT CAA 407
 Phe Ser Ser Tyr His Gly Thr Lys Pro Gly Tyr Val Asp Ser Ile Gln
 20 25 30
 AAA GGT ATA CAA AAG CCA AAA TCT GGT ACA CAA GGA AAT TAT GAC GAT 455
 Lys Gly Ile Gln Lys Pro Lys Ser Gly Thr Gln Gly Asn Tyr Asp Asp
 35 40 45
 GAT TGG AAA GGG TTT TAT AGT ACC GAC AAT AAA TAC GAC GCT GCG GGA 503
 Asp Trp Lys Gly Phe Tyr Ser Thr Asp Asn Lys Tyr Asp Ala Ala Gly
 50 55 60
 TAC TCT GTA GAT AAT GAA AAC CCG CTC TCT GGA AAA GCT GGA GGC GTG 551
 Tyr Ser Val Asp Asn Glu Asn Pro Leu Ser Gly Lys Ala Gly Gly Val
 65 70 75 80
 GTC AAA GTG ACG TAT CCA GGA CTG ACG AAG GTT CTC GCA CTA AAA GTG 559
 Val Lys Val Thr Tyr Pro Gly Leu Thr Lys Val Leu Ala Leu Lys Val
 85 90 95
 GAT AAT GCC GAA ACT ATT AAG AAA GAG TTA GGT TTA AGT CTC ACT GAA 647
 Asp Asn Ala Glu Thr Ile Lys Lys Glu Leu Gly Leu Ser Leu Thr Glu
 100 105 110
 CCG TTG ATG GAG CAA GTC GGA ACG GAA GAG TTT ATC AAA AGG TTC GGT 695
 Pro Leu Met Glu Gln Val Gly Thr Glu Glu Phe Ile Lys Arg Phe Gly
 115 120 125

- 33 -

GAT Asp 130	GGT Gly 130	GCT Ala 130	TCG Ser 130	CGT Arg 130	GTA Val 130	GTG Val 135	CTC Leu 135	AGC Ser 135	CTT Leu 135	CCC Pro 140	TTC Phe 140	GCT Ala 140	GAG Glu 140	GGG Gly 140	AGT Ser 140	743
TCT Ser 145	AGC Ser 145	GTT Val 145	GAA Glu 145	TAT Tyr 145	ATT Ile 150	AAT Asn 150	AAC Asn 150	TGG Trp 150	GAA Glu 155	CAG Gln 155	GCG Ala 155	AAA Lys 155	GCG Ala 160	TTA Leu 160	AGC Ser 160	791
GTA Val 165	GAA Glu 165	CTT Leu 165	GAG Glu 165	ATT Ile 165	AAT Asn 165	TTT Phe 170	GAA Glu 170	ACC Thr 170	CGT Arg 170	GGA Gly 175	AAA Lys 175	CGT Arg 175	GGC Gly 175	CAA Gln 175	GAT Asp 175	839
GCG Ala 180	ATG Met 180	TAT Tyr 180	GAG Glu 180	TAT Tyr 180	ATG Met 185	GCT Ala 185	CAA Gln 185	GCC Ala 185	TGT Cys 185	GCA Ala 190	GGA Gly 190	AAT Asn 190	CGT Arg 190	GTC Val 190	AGG Arg 190	887
CGA Arg 195	TCA Ser 195	GTA Val 195	GGT Gly 195	AGC Ser 195	TCA Ser 200	TTG Leu 200	TCA Ser 200	TGC Cys 200	ATA Ile 205	AAT Asn 205	CTT Leu 205	GAT Asp 205	TGG Trp 205	GAT Asp 205	GTC Val 205	935
ATA Ile 210	AGG Arg 210	GAT Asp 210	AAA Lys 210	ACT Thr 215	AAG Lys 215	ACA Thr 215	AAG Lys 215	ATA Ile 215	GAG Glu 220	TCT Ser 220	TTG Leu 220	AAA Lys 220	GAG Glu 220	CAT His 220	GGC Gly 220	983
CCT Pro 225	ATC Ile 225	AAA Lys 225	AAT Asn 225	AAA Lys 230	ATG Met 230	AGC Ser 230	GAA Glu 230	AGT Ser 235	CCC Pro 235	AAT Asn 235	AAA Lys 235	ACA Thr 235	GTA Val 240	TCT Ser 240	GAG Glu 240	1031
GAA Glu 245	AAA Lys 245	GCT Ala 245	AAA Lys 245	CAA Gln 245	TAC Tyr 245	CTA Leu 250	GAA Glu 250	GAA Glu 250	TTT Phe 250	CAT His 255	CAA Gln 255	ACG Thr 255	GCA Ala 255	TTA Leu 255	GAG Glu 255	1079
CAT His 260	CCT Pro 260	GAA Glu 260	TTG Leu 260	TCA Ser 260	GAA Glu 265	CTT Leu 265	AAA Lys 265	ACC Thr 265	GTT Val 265	ACT Thr 270	GGG Gly 270	ACC Thr 270	AAT Asn 270	CCT Pro 270	GTA Val 270	1127
TTC Phe 275	GCT Ala 275	GGG Gly 275	GCT Ala 280	AAC Asn 280	TAT Tyr 280	GCG Ala 280	GCG Ala 280	TGG Trp 285	GCA Ala 285	GTA Val 285	AAC Asn 285	GTT Val 285	GCG Ala 285	CAA Gln 285	GTT Val 285	1175
ATC Ile 290	GAT Asp 290	AGC Ser 290	GAA Glu 295	ACA Thr 295	GCT Ala 295	GAT Asp 295	AAT Asn 300	TTG Leu 300	GAA Glu 300	AAG Lys 300	ACA Thr 300	ACT Thr 300	GCT Ala 300	GCT Ala 300	CTT Leu 300	1223
TCG Ser 305	ATA Ile 305	CTT Leu 310	CCT Pro 310	GGT Gly 310	ATC Ile 310	GGT Gly 315	AGC Ser 315	GTA Val 315	ATG Met 315	GGC Gly 315	ATT Ile 315	GCA Ala 315	GAC Asp 315	GGT Gly 320	GCC Ala 320	1271
GTT Val 325	CAC His 325	CAC His 325	AAT Asn 325	ACA Thr 325	GAA Glu 330	GAG Glu 330	ATA Ile 330	GTG Val 330	GCA Ala 330	CAA Gln 335	TCA Ser 335	ATA Ile 335	GCT Ala 335	TTA Leu 335	TCG Ser 335	1319
TCT Ser 340	TTA Leu 340	ATG Met 340	GTT Val 340	GCT Ala 340	CAA Gln 345	GCT Ala 345	ATT Ile 345	CCA Pro 345	TTG Leu 345	GTA Val 350	GGA Gly 350	GAG Glu 350	CTA Leu 350	GTT Val 350	GAT Asp 350	1367
ATT Ile 355	GGT Gly 355	TTC Phe 355	GCT Ala 360	GCA Ala 360	TAT Tyr 360	AAT Asn 360	TTT Phe 360	GTA Val 365	GAG Glu 365	AGT Ser 365	ATT Ile 365	ATC Ile 365	AAT Asn 365	TTA Leu 365	TTT Phe 365	1415

- 34 -

CAA GTA GTT CAT AAT TCG TAT AAT CGT CCC GCG TAT TCT CCG GGG CAT 1463
 Gln Val Val His Asn Ser Tyr Asn Arg Pro Ala Tyr Ser Pro Gly His
 370 375 380

AAA ACG CAA CCA TTT CTT CAT GAC GGG TAT GCT GTC AGT TGG AAC ACT 1511
 Lys Thr Gln Pro Phe Leu His Asp Gly Tyr Ala Val Ser Trp Asn Thr
 385 390 395 400

GTT GAA GAT TCG ATA ATC CGA ACT GGT TTT CAA GGG GAG AGT GGG CAC 1559
 Val Glu Asp Ser Ile Ile Arg Thr Gly Phe Gln Gly Glu Ser Gly His
 405 410 415

GAC ATA AAA ATT ACT GCT GAA AAT ACC CCG CTT CCA ATC GCG GGT GTC 1607
 Asp Ile Lys Ile Thr Ala Glu Asn Thr Pro Leu Pro Ile Ala Gly Val
 420 425 430

CTA CTA CCG ACT ATT CCT GGA AAG CTG GAC GTT AAT AAG TCC AAG ACT 1655
 Leu Leu Pro Thr Ile Pro Gly Lys Leu Asp Val Asn Lys Ser Lys Thr
 435 440 445

CAT ATT TCC GTA AAT GGT CGG AAA ATA AGG ATG CGT TGC AGA GCT ATA 1703
 His Ile Ser Val Asn Gly Arg Lys Ile Arg Met Arg Cys Arg Ala Ile
 450 455 460

GAC GGT GAT GTA ACT TTT TGT CGC CCT AAA TCT CCT GTT TAT GTT GGT 1751
 Asp Gly Asp Val Thr Phe Cys Arg Pro Lys Ser Pro Val Tyr Val Gly
 465 470 475 480

AAT GGT GTG CAT GCG AAT CTT CAC GTG GCA TTT CAC AGA AGC AGC TCG 1799
 Asn Gly Val His Ala Asn Leu His Val Ala Phe His Arg Ser Ser Ser
 485 490 495

GAG AAA ATT CAT TCT AAT GAA ATT TCG TCG GAT TCC ATA GGC GTT CTT 1847
 Glu Lys Ile His Ser Asn Glu Ile Ser Ser Asp Ser Ile Gly Val Leu
 500 505 510

GGG TAC CAG AAA ACA GTA GAT CAC ACC AAG GTT AAT TCT AAG CTA TCG 1895
 Gly Tyr Gln Lys Thr Val Asp His Thr Lys Val Asn Ser Lys Leu Ser
 515 520 525

CTA TTT TTT GAA ATC AAA AGC TGAAAGGTAG TGGGGTCGTG TGCCGG 1942
 Leu Phe Phe Glu Ile Lys Ser
 530 535

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 2:

(1) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1942
 (B) TYPE: nucleic acid
 (C) STRANDEDNESS: double
 (D) TOPOLOGY: linear

(ix) FEATURE:

(D) OTHER INFORMATION: Xaa in location 516 is either Cys, Phe, Glu or Ala; Xaa in location 526 is either Cys, Phe, Glu, or Ala; Xaa in location 530 is either Glu, Lys, Gln or Ala; Xaa in location 534 is either Cys, Phe, Glu, or Ala.

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

CCGGCGTTGC GTATCCAGTG GCTACACTCA GGTGTGAATG ATTGGGATGA TGTACCTGAT

- 35 -

CTGAGAGCGA TTAAAACTC ATTGAGGAGT AGGTCCCGAT TGGTTTTTGC TAGTGAAGCT	120
TAGCTAGCTT TCCCCATGTA ACCAATCTAT CAAAAAAGGG CATTGATTTC AGAGCACCT	180
TATAATTAGG ATAGCTTTAC CTAATTATTT TATGAGTCCT GGTAAGGGGA TACGTTGTGA	240
GCAGAAACT GTTTGCGTCA ATCTTAATAG GGGCGCTACT GGGGATAGGG GCCCCACCTT	300
CAGCCCATGC A	311
GGC GCT GAT GAT GTT GTT GAT TCT TCT AAA TCT TTT GTG ATG GAA AAC Gly Ala Asp Asp Val Val Asp Ser Ser Lys Ser Phe Val Met Glu Asn 1 5 10 15	359
TTT TCT TCG TAC CAC GGG ACT AAA CCT GGT TAT GTA GAT TCC ATT CAA Phe Ser Ser Tyr His Gly Thr Lys Pro Gly Tyr Val Asp Ser Ile Gln 20 25 30	407
AAA GGT ATA CAA AAG CCA AAA TCT GGT ACA CAA GGA AAT TAT GAC GAT Lys Gly Ile Gln Lys Pro Lys Ser Gly Thr Gln Gly Asn Tyr Asp Asp 35 40 45	455
GAT TGG AAA GGG TTT TAT AGT ACC GAC AAT AAA TAC GAC GCT GCG GGA Asp Trp Lys Gly Phe Tyr Ser Thr Asp Asn Lys Tyr Asp Ala Ala Gly 50 55 60	503
TAC TCT GTA GAT AAT GAA AAC CCG CTC TCT GGA AAA GCT GGA GGC GTG Tyr Ser Val Asp Asn Glu Asn Pro Leu Ser Gly Lys Ala Gly Gly Val 65 70 75 80	551
GTC AAA GTG ACG TAT CCA GGA CTG ACG AAG GTT CTC GCA CTA AAA GTG Val Lys Val Thr Tyr Pro Gly Leu Thr Lys Val Leu Ala Leu Lys Val 85 90 95	559
GAT AAT GCC GAA ACT ATT AAG AAA GAG TTA GGT TTA AGT CTC ACT GAA Asp Asn Ala Glu Thr Ile Lys Lys Glu Leu Gly Leu Ser Leu Thr Glu 100 105 110	647
CCG TTG ATG GAG CAA GTC GGA ACG GAA GAG TTT ATC AAA AGG TTC GGT Pro Leu Met Glu Gln Val Gly Thr Glu Glu Phe Ile Lys Arg Phe Gly 115 120 125	695
GAT GGT GCT TCG CGT GTA GTG CTC AGC CTT CCC TTC GCT GAG GGG AGT Asp Gly Ala Ser Arg Val Val Leu Ser Leu Pro Phe Ala Glu Gly Ser 130 135 140	743
TCT AGC GTT GAA TAT ATT AAT AAC TGG GAA CAG GCG AAA GCG TTA AGC Ser Ser Val Glu Tyr Ile Asn Asn Trp Glu Gln Ala Lys Ala Leu Ser 145 150 155 160	791
GTA GAA CTT GAG ATT AAT TTT GAA ACC CGT GGA AAA CGT GGC CAA GAT Val Glu Leu Glu Ile Asn Phe Glu Thr Arg Gly Lys Arg Gly Gln Asp 165 170 175	839
GCG ATG TAT GAG TAT ATG GCT CAA GCC TGT GCA GGA AAT CGT GTC AGG Ala Met Tyr Glu Tyr Met Ala Gln Ala Cys Ala Gly Asn Arg Val Arg 180 185 190	887
CGA TCA GTA GGT AGC TCA TTG TCA TGC ATA AAT CTT GAT TGG GAT GTC Arg Ser Val Gly Ser Ser Leu Ser Cys Ile Asn Leu Asp Trp Asp Val 195 200 205	935

- 36 -

ATA AGG GAT AAA ACT AAG ACA AAG ATA GAG TCT TTG AAA GAG CAT GGC Ile Arg Asp Lys Thr Lys Thr Lys Ile Glu Ser Leu Lys Glu His Gly 210 215 220	983
CCT ATC AAA AAT AAA ATG AGC GAA AGT CCC AAT AAA ACA GTA TCT GAG Pro Ile Lys Asn Lys Met Ser Glu Ser Pro Asn Lys Thr Val Ser Glu 225 230 235 240	1031
GAA AAA GCT AAA CAA TAC CTA GAA GAA TTT CAT CAA ACG GCA TTA GAG Glu Lys Ala Lys Gln Tyr Leu Glu Glu Phe His Gln Thr Ala Leu Glu 245 250 255	1079
CAT CCT GAA TTG TCA GAA CTT AAA ACC GTT ACT GGG ACC AAT CCT GTA His Pro Glu Leu Ser Glu Leu Lys Thr Val Thr Gly Thr Asn Pro Val 260 265 270	1127
TTC GCT GGG GCT AAC TAT GCG GCG TGG GCA GTA AAC GTT GCG CAA GTT Phe Ala Gly Ala Asn Tyr Ala Ala Trp Ala Val Asn Val Ala Gln Val 275 280 285	1175
ATC GAT AGC GAA ACA GCT GAT AAT TTG GAA AAG ACA ACT GCT GCT CTT Ile Asp Ser Glu Thr Ala Asp Asn Leu Glu Lys Thr Thr Ala Ala Leu 290 295 300	1223
TCG ATA CTT CCT GGT ATC GGT AGC GTA ATG GGC ATT GCA GAC GGT GCC Ser Ile Leu Pro Gly Ile Gly Ser Val Met Gly Ile Ala Asp Gly Ala 305 310 315 320	1271
GTT CAC CAC AAT ACA GAA GAG ATA GTG GCA CAA TCA ATA GCT TTA TCG Val His His Asn Thr Glu Glu Ile Val Ala Gln Ser Ile Ala Leu Ser 325 330 335	1319
TCT TTA ATG GTT GCT CAA GCT ATT CCA TTG GTA GGA GAG CTA GTT GAT Ser Leu Met Val Ala Gln Ala Ile Pro Leu Val Gly Glu Leu Val Asp 340 345 350	1367
ATT GGT TTC GCT GCA TAT AAT TTT GTA GAG AGT ATT ATC AAT TTA TTT Ile Gly Phe Ala Ala Tyr Asn Phe Val Glu Ser Ile Ile Asn Leu Phe 355 360 365	1415
CAA GTA GTT CAT AAT TCG TAT AAT CGT CCC GCG TAT TCT CCG GGG CAT Gln Val Val His Asn Ser Tyr Asn Arg Pro Ala Tyr Ser Pro Gly His 370 375 380	1463
AAA ACG CAA CCA TTT CTT CAT GAC GGG TAT GCT GTC AGT TGG AAC ACT Lys Thr Gln Pro Phe Leu His Asp Gly Tyr Ala Val Ser Trp Asn Thr 385 390 395 400	1511
GTT GAA GAT TCG ATA ATC CGA ACT GGT TTT CAA GGG GAG AGT GGG CAC Val Glu Asp Ser Ile Ile Arg Thr Gly Phe Gln Gly Glu Ser Gly His 405 410 415	1559
GAC ATA AAA ATT ACT GCT GAA AAT ACC CCG CTT CCA ATC GCG GGT GTC Asp Ile Lys Ile Thr Ala Glu Asn Thr Pro Leu Pro Ile Ala Gly Val 420 425 430	1607
CTA CTA CCG ACT ATT CCT GGA AAG CTG GAC GTT AAT AAG TCC AAG ACT Leu Leu Pro Thr Ile Pro Gly Lys Leu Asp Val Asn Lys Ser Lys Thr 435 440 445	1655
CAT ATT TCC GTA AAT GGT CGG AAA ATA AGG ATG CGT TGC AGA GCT ATA His Ile Ser Val Asn Gly Arg Lys Ile Arg Met Arg Cys Arg Ala Ile 450 455 460	1703

- 37 -

GAC GGT GAT GTA ACT TTT TGT CGC CCT AAA TCT CCT GTT TAT GTT GGT Asp Gly Asp Val Thr Phe Cys Arg Pro Lys Ser Pro Val Tyr Val Gly 465 470 475 480	1751
AAT GGT GTG CAT GCG AAT CTT CAC GTG GCA TTT CAC AGA AGC AGC TCG Asn Gly Val His Ala Asn Leu His Val Ala Phe His Arg Ser Ser Ser 485 490 495	1799
GAG AAA ATT CAT TCT AAT GAA ATT TCG TCG GAT TCC ATA GGC GTT CTT Glu Lys Ile His Ser Asn Glu Ile Ser Ser Asp Ser Ile Gly Val Leu 500 505 510	1847
GGG TAC CAG KNN ACA GTA GAT CAC ACC AAG GTT AAT TCT KNN CTA TCG Gly Tyr Gln Xaa Thr Val Asp His Thr Lys Val Asn Ser Xaa Leu Ser 515 520 525	1895
CTA VMN TTT GAA ATC KNN AGC TGAAAGGTAG TGGGGTCGTG TGCCGG Leu Xaa Phe Glu Ile Xaa Ser 530 535	1942

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 3:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

CGGATTCCAT AAGTGTTCTT GGGTA	25
-----------------------------	----

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

CCATAGGCGT TGAAGGGTAC CAGAA	25
-----------------------------	----

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

- 38 -

GCGTTCTTGG GGCCCAGAAA ACAGT

25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

TTGGGTACCA GGAAACAGTA GATCA

25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 7:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

ACCAGAAAAC AGAAGATCAC ACCAA

25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 8:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

AAACAGTAGA TGACACCAAG GTTAA

25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

CAGTAGATCA CCGCAAGGTT AATTC

25

- 39 -

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 10:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

TAGATCACAC CGAGGTTAAT TCTAA 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

ATCACACCAA GGAAAATTCT AAGCT 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 12:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

ACACCAAGGT TGCTTCTAAG CTATC 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

CCAAGGTAA TTTAAGCTA TCGCT 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 14:

(i) SEQUENCE CHARACTERISTICS:

- 40 -

(A) LENGTH: 25
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

AGGTTAATTC TGAGCTATCG CTATT 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

ATTCTAAGCT ATATCTATTT TTTGA 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

AGCTATCGCT ATCTTTTGAA ATCAA 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 17:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

GCGTTCTTGG GGCCCAGAAA ACAGT 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 18:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

- 41 -

(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

TTGGGTACCA GGCAACAGTA GATCA 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

ACCAGAAAAC AGCAGATCAC ACCAA 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

AAACAGTAGA TGCCACCAAG GTTAA 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

CAGTAGATCA CGCCAAGGTT AATTC 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 25
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

- 42 -

TAGATCACAC CGCGGTTAAT TCTAA 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

ATCACACCAA GGCTAATTCT AAGCT 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 24:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

ACACCAAGGT TGCTTCTAAG CTATC 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 25:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

CCAAGGTAA TGCTAAGCTA TCGCT 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 26:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

AGGTTAATTC TCGCTATCG CTATT 25

- 43 -

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 27:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

ATTCTAAGCT AGCGCTATTT TTTGA 25

(2) INFORMATION FOR SEQUENCE IDENTIFICATION NUMBER: 28:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH:	25
(B) TYPE:	nucleic acid
(C) STRANDEDNESS:	single
(D) TOPOLOGY:	linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

AGCTATCGCT AGCTTTTGAA ATCAA 25

- 44 -

CLAIMS

1. A polypeptide comprising a mutant diphtheria toxin R domain, said R domain comprising a mutation in at least one or more of Lys 516, Lys 526, Phe 530, or Lys 534 of wild-type diphtheria toxin (Fig. 1; SEQ ID NO: 1).
2. The polypeptide of claim 1, in which at least one or more of said Lys 516, Lys 526, or Lys 534 is replaced by either Cys or Phe.
3. The polypeptide of claim 1, in which said Phe 530 is substituted by any one of Glu, Lys, or Gln.
4. The polypeptide of any one of claims 1-3, said polypeptide further comprising at least part of diphtheria toxin fragment B, said fragment B lacking the segment between amino acids 379-535, inclusively, of wild-type diphtheria toxin (Fig. 1; SEQ ID NO: 1).
5. The polypeptide of any one of claims 1-3, said polypeptide comprising at least part of diphtheria toxin fragment A.
6. The polypeptide of claim 4, said polypeptide comprising at least part of diphtheria toxin fragment A.
7. The polypeptide of claim 4, said polypeptide comprising all of diphtheria toxin fragment A.
8. A substantially pure preparation of the polypeptide of any one of claims 1-3.
9. A substantially pure preparation of the polypeptide of claim 4.

- 45 -

10. A substantially pure preparation of the polypeptide of claim 5.

11. A cell comprising a nucleic acid encoding the polypeptide of any one of claims 1-3.

12. A cell comprising a nucleic acid encoding the polypeptide of claim 4.

13. A cell comprising a nucleic acid encoding the polypeptide of claim 5.

14. The cell of claim 11, wherein said cell is any one of a *B. subtilis*, *BCG*, *Salmonella sp.*, *Vibrio cholerae*, *Listeriae*, *Yersinia*, *Streptococci*, *Corynebacterium diphtheriae*, or an *E. coli* cell.

15. The cell of claim 12, wherein said cell is any one of a *B. subtilis*, *BCG*, *Salmonella sp.*, *Vibrio cholerae*, *Listeriae*, *Yersinia*, *Streptococci*, *Corynebacterium diphtheriae*, or an *E. coli* cell.

16. The cell of claim 13, wherein said cell is any one of *B. subtilis*, *BCG*, *Salmonella sp.*, *Vibrio cholerae*, *Listeriae*, *Yersinia*, *Streptococci*, *Corynebacterium diphtheriae*, or an *E. coli* cell.

17. A vaccine comprising a physiologically acceptable mixture including the polypeptide of any one of claims 1-3.

18. A vaccine comprising a physiologically acceptable mixture including the polypeptide of claim 4.

- 46 -

19. A vaccine comprising a physiologically acceptable mixture including the polypeptide of claim 5.

20. A live vaccine strain comprising the cell of claim 14.

21. A live vaccine strain comprising the cell of claim 15.

22. A live vaccine strain comprising the cell of claim 16.

23. A method of preparing a polypeptide comprising

 providing the cell of claim 14,
 growing said cell in a medium to form a population of cells that express said polypeptide, and
 obtaining said polypeptide from said population of cells or said medium.

24. A method of preparing a polypeptide comprising

 providing the cell of claim 15,
 growing said cell in a medium to form a population of cells that express said polypeptide, and
 obtaining said polypeptide from said population of cells or said medium.

- 47 -

25. A method of preparing a polypeptide comprising

providing the cell of claim 16,
growing said cell in a medium to form a population of cells that express said polypeptide, and
obtaining said polypeptide from said population of cells or said medium.

26. A method for manufacturing a vaccine comprising culturing the cell of claim 14 under conditions permitting proliferation of said cell, wherein said cell is suitable for introduction into an animal as a live vaccine cell.

27. A method for manufacturing a vaccine comprising culturing the cell of claim 15 under conditions permitting proliferation of said cell, wherein said cell is suitable for introduction into an animal as a live vaccine cell.

28. A method for manufacturing a vaccine comprising culturing the cell of claim 16 under conditions permitting proliferation of said cell, wherein said cell is suitable for introduction into an animal as a live vaccine cell.

29. A method for immunizing a mammal against wild-type diphtheria toxin, comprising introducing an immunizing amount of the vaccine of claim 17 into said mammal.

30. A method for immunizing a mammal against wild-type diphtheria toxin, comprising introducing an immunizing amount of the vaccine of claim 18 into said mammal.

- 48 -

31. A method for immunizing a mammal against wild-type diphtheria toxin, comprising introducing an immunizing amount of the vaccine of claim 19 into said mammal.

32. The method of claim 29, wherein said mammal is a human.

33. The method of claim 30, wherein said mammal is a human.

34. The method of claim 31, wherein said mammal is a human.

35. A fusion polypeptide comprising the polypeptide of any one of claims 1-3, linked by a peptide bond to a second polypeptide.

36. A fusion polypeptide comprising the polypeptide of claim 4 linked by a peptide bond to a second polypeptide.

37. A fusion polypeptide comprising the polypeptide of claim 5 linked by a peptide bond to a second polypeptide.

38. A DNA molecule comprising a sequence encoding a mutant diphtheria toxin R domain, wherein the DNA sequence complimentary to the codon corresponding to at least one of Lys 516, Lys 526, Phe 530, or Lys 534 of naturally-occurring diphtheria toxin (Fig. 1; SEQ ID NO: 1) is mutated.

39. The DNA molecule of claim 38, wherein said mutant DNA sequence complimentary to the codon

- 49 -

corresponding to at least one of Lys 516, Lys 526, or Lys 534 encodes either Cys or Phe.

40. The DNA molecule of claim 38, said mutant DNA sequence complimentary to the codon corresponding to Phe 530 encodes any one of Glu, Lys, or Gln.

41. The DNA molecule of any one of claims 38-40, wherein said DNA molecule encodes at least part of diphtheria toxin fragment B, said fragment B lacking the segment between amino acids 379-535, inclusively.

42. The DNA molecule of any one of claims 38-40, wherein said DNA molecule encodes at least part of the diphtheria toxin fragment A.

43. The DNA molecule of claim 41, wherein said molecule encodes at least part of fragment A.

44. The DNA molecule of claim 42, wherein said molecule encodes all of fragment A.

45. The DNA molecule of claim 41, said fragment B comprising a mutation at any one of Glu 349, Asp 352, or Ile 364 of wild-type diphtheria toxin (Fig. 1, SEQ ID NO: 1).

46. The DNA molecule of claim 42, said fragment A comprising a mutation at His 21, Glu 22, Lys 39, Gly 52, Gly 79, Gly 128, Ala 158, Gly 162, Glu 142, Val 147, Glu 148 of wild-type diphtheria toxin (Fig. 1; SEQ ID NO: 1).

47. A DNA sequence encoding the polypeptide encoded by the DNA sequence shown in Fig. 2 (SEQ ID NO: 2).

- 50 -

48. A polyclonal antibody produced by injecting a mammal with the diphtheria toxin R domain.

49. A monoclonal antibody capable of binding the diphtheria toxin receptor binding region.

50. A polypeptide comprising a mutant R domain, wherein said R domain comprises at least one mutation between amino acids 379-535 (SEQ ID NO: 1), inclusive; said polypeptide binding sensitive cells with less affinity than wild-type diphtheria toxin and being capable of forming an immune complex with an antibody which specifically recognizes the R domain of wild-type diphtheria toxin.

51. A DNA molecule comprising a sequence encoding a mutant diphtheria toxin R domain, wherein the DNA sequence complimentary to a codon corresponding to at least one amino acid between 379-535 (SEQ ID NO: 1), inclusive, is mutated.




FIG. 1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/06857

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : 424/184.1, 183.1; 530/350; 435/69.1, 69.7, 29.0

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/184.1, 183.1; 530/350; 435/69.1, 69.7, 29.0

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 4,709,017 (COLLIER ET AL.) 24 Nov 1987, abstract, cols. 2-3, col. 4, l. 30-41, claims.	1-10, 17-25, 29-37, 50
Y	Vaccines 93, issued 1993, H. Fu et al., "Receptor-binding domain of diphtheria toxin as a potential immunogen", pages 379-383, see entire document.	1-10, 17-25, 29-37, 50
Y	Proc. Natl. Acad. Sci., USA, Volume 89, issued July 1992, K. P. Killeen et al, "Reversion of recombinant toxoids: Mutations in diphtheria toxin that partially compensate for active-site deletions", pages 6207-6209, see entire document.	1-10, 17-25, 29-37, 50

☒ Further documents are listed in the continuation of Box C.☐ See patent family annex.

Special categories of cited documents:			
"A"	documents defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

07 AUGUST 1995

Date of mailing of the international search report

13 OCT 1995

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

NITA M. MINNIFIELD

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/06857

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Science, Volume 238, issued 23 October 1987, L. Greenfield et al, "Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity", pages 536-539, see entire document.	1-10, 17-25, 29-37, 50
A	FASEB J. Volume 5, issued 1991, J. M. Rolf et al, "Further characterization of the diphtheria toxin receptor-binding domain within HA6DT", A821, see abstract	1-10, 17-25, 29-37, 50
Y	Gen. Meet. Am. Soc. Microbiol., Volume 91, issued 1991, J. M. Rolf et al, "Molecular characterization and antibody-facilitated epitope mapping analyses of the diphtheria toxin receptor-binding domain within HA6DT", page 75, abstract.	1-10, 17-25, 29-37, 50
A	J. Biol. Chem., Volume 265, No. 13, issued 05 May 1990, J. M. Rolf et al, "Localization of the diphtheria toxin receptor-binding to the carboxyl-terminal Mr 6000 region of the toxin", pages 7331-7337, see entire document.	1-10, 17-25, 29-37, 50
A	Proc. Natl. Acad. Sci., USA, Volume 80, issued November 1983, L. Greenfield et al, "Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage B", pages 6853-6857, see entire document.	1-10, 17-25, 29-37, 50

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/06857

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-10, 17-25, 29-37, and 50

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/06857

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

A61K 39/00, 39/38, 39/40, 39/395, 39/44, 39/42; C07K 1/00, 14/00, 17/00; C12P 21/06; C12Q 1/02

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, MEDLINE, HCAPLUS, BIOSIS

author/inventor name, diphtheria, toxin, mutant, receptor, receptor binding domain, polypeptide, r domain, bcg, cell culture, Salmonella, vaccine, Vibrio cholerae, immunization, Listeriae, E. coli, Streptococci, Corynebacterium

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-10, 17-25, 29-37, and 50, drawn to a polypeptide/fusion polypeptide, method of preparing and use, vaccines and method of immunizing.

Group II, claims 11-16, drawn to cells.

Group III, claims 26-28, drawn to a method of manufacture.

Group IV, claims 38-47 and 51, drawn to a DNA molecule.

Group V, claims 48-49, drawn to polyclonal and monoclonal antibodies.

The inventions listed as Groups I, II, III, IV, and V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The Groups are drawn to immunologically, structurally, biochemically, and functionally distinct entities.